Clinical Report: Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma
Background
Chronic subdural hematoma (CSDH) is a prevalent condition among the elderly, with increasing incidence rates expected due to demographic shifts. Standard surgical treatments, such as burr-hole craniotomy, have significant recurrence rates, prompting interest in alternative therapies like MMAE.
Data Highlights
Recent randomized controlled trials have shown mixed results regarding the efficacy of MMAE in reducing recurrence rates of CSDH. Some studies reported lower rates of treatment failure, while others did not achieve significant primary endpoints.
Key Findings
MMAE has emerged as a minimally invasive treatment option for CSDH, targeting the arterial supply to pathological neomembranes.
Recurrence rates after standard burr-hole craniotomy remain high, necessitating alternative treatment strategies.
Recent trials, such as EMBOLISE and STEM, showed varying results for MMAE, while MAGIC-MT did not demonstrate significant reductions in recurrence.
The pathophysiology of CSDH involves inflammation, angiogenesis, and coagulation.
Clinical Implications
MMAE may serve as an adjunctive or alternative treatment for CSDH, particularly in patients at high risk for recurrence after standard surgical interventions. Understanding the biological mechanisms of CSDH can aid in patient selection and treatment planning.
Conclusion
MMAE represents a promising approach for managing CSDH, although current evidence is heterogeneous. Continued research is essential to establish its role in routine clinical practice.
Qualitative interviews identified four themes involving emergency challenges and response, teamwork, psychological stress and coping, and professional growth needs in trauma surgery.
